MPN Watch

Scan run #2

Started 02-may-2026 17:09 · still running · triggered by cron

Items fetched Relevant Stored New pages
0 0 0 0

New pages this run

The "" New pages column above counts new wiki pages created across every area (the column name new_mechanisms is a v1 holdover — it covers mechanisms + treatments + subtypes + transplant-timing + symptoms + lifestyle).

Area Page Mentions to date
Lifestyle & Environmental Factors Ascorbic Acid (Vitamin C) Supplementation 1
Lifestyle & Environmental Factors Hyperbaric Oxygen Therapy (environmental/oxygen intervention) 1
Mechanisms & Pathways Acquired von Willebrand syndrome in MPN 1
Mechanisms & Pathways BCL-2/BCL-xL dual inhibition and apoptotic dependence in myeloid neoplasms 1
Mechanisms & Pathways BET bromodomain epigenetic regulation in MPN 1
Mechanisms & Pathways BET bromodomain inhibition in MPN 1
Mechanisms & Pathways Blast-phase MPN and leukemic transformation 26
Mechanisms & Pathways Bone marrow macrophage microenvironment in CMML 1
Mechanisms & Pathways Bone marrow mast-cell infiltration and pruritus in MPN 1
Mechanisms & Pathways CD4-directed CAR-T cell therapy (CD4CAR) in CMML 1
Mechanisms & Pathways CREB3L1 mRNA as lineage-associated biomarker in MPN 1
Mechanisms & Pathways CSF1R macrophage/monocyte signaling in MPN 1
Mechanisms & Pathways Complement C3-driven stromal reprogramming in MPN 1
Mechanisms & Pathways Cytopenic vs proliferative PMF phenotypes 1
Mechanisms & Pathways DDX5 RNA helicase scaffolding co-activator in JAK2/MYC signaling 1
Mechanisms & Pathways DNMT3A mutations 1
Mechanisms & Pathways EZH2 mutations 1
Mechanisms & Pathways Eltrombopag (TPO-R agonism) and selective TET2-mutant clone suppression 1
Mechanisms & Pathways Endothelial-to-mesenchymal transition in MPN cardiovascular disease 1
Mechanisms & Pathways Erythrocyte rigidity and clot pathology in JAK2-MPN 1
Mechanisms & Pathways Ferroptosis in MPN and hematological malignancies 1
Mechanisms & Pathways Fibrocytes as collagen-producing drivers of BM fibrosis in MPN 1
Mechanisms & Pathways Galectin-1 / TLR4 / NF-κB monocyte inflammation axis in MPN 1
Mechanisms & Pathways Glutamate–mGluR5–fumarate metabolic rewiring of MSCs 1
Mechanisms & Pathways Immune microenvironment dysregulation in MPN 1
Mechanisms & Pathways Inducible caspase-9 (iCasp9) suicide gene T-cell elimination mechanism 1
Mechanisms & Pathways JAK2-driven vasculopathy and thoracic aortic aneurysm 1
Mechanisms & Pathways JAK2V617F allele dosage and HSC transcriptional priming 1
Mechanisms & Pathways JAK2V617F-mutated hemogenic endothelium as cell of origin in PMF 1
Mechanisms & Pathways Lysozyme-associated nephropathy mechanism 1
Mechanisms & Pathways MDM2–p53 axis in MPN 1
Mechanisms & Pathways MF spleen spatial niche compartments (IV/PV/RP) 1
Mechanisms & Pathways MPN clonal evolution trajectories to transformation 8
Mechanisms & Pathways MPN-associated IgA nephropathy and IL-6/IL-11 mesangial axis 1
Mechanisms & Pathways MPN-specific antigens and anti-MPN T cell receptors 1
Mechanisms & Pathways Metabolic syndrome as a pathophysiological modifier in polycythemia vera 1
Mechanisms & Pathways Mutant IDH1 and 2-hydroxyglutarate oncometabolite signaling 1
Mechanisms & Pathways Mutant-selective JAK2V617F inhibition via JH2 pseudokinase domain 7
Mechanisms & Pathways NF-κB signaling in MPN 1
Mechanisms & Pathways NK cell immune surveillance in MPN 1
Mechanisms & Pathways Oxidative stress in MPN 1
Mechanisms & Pathways Oxidative stress, lipid peroxidation, and malondialdehyde (MDA) 1
Mechanisms & Pathways PIM kinase signaling in MPN 1
Mechanisms & Pathways PIM1 kinase signaling in MPN 1
Mechanisms & Pathways SLAMF7-directed immunotherapy in MPN 1
Mechanisms & Pathways TMPRSS6 inhibition and hepcidin-mediated iron restriction in PV 1
Mechanisms & Pathways TP53 mutations in MPN 1
Mechanisms & Pathways TPO/MPL signaling axis 1
Mechanisms & Pathways TYK2 signaling dependency in CALR/MPL-mutant MPN 1
Mechanisms & Pathways Telomerase inhibition in MPN 1
Mechanisms & Pathways Therapy-associated mutagenesis in MPN 1
Mechanisms & Pathways Thrombopoietin/MPL signaling in endocardial endothelium 1
Mechanisms & Pathways Type II JAK2 inhibition (inactive-conformation) 1
Mechanisms & Pathways UTS (U2AF1/TP53/SRSF2) high-risk mutation signature in SMF 1
Mechanisms & Pathways m6A epitranscriptomic regulation in MPN 1
Disease Subtypes Advanced systemic mastocytosis (AdvSM) 1
Disease Subtypes Blast-phase MPN and leukemic transformation 23
Disease Subtypes Juvenile myelomonocytic leukemia (JMML) 2
Disease Subtypes MDS/MPN with neutrophilia (aCML) 1
Disease Subtypes MPN (general) 90
Disease Subtypes Myeloid/lymphoid neoplasms with PCM1::JAK2 (MLN-JAK2) 1
Disease Subtypes Prefibrotic myelofibrosis (preMF) 6
Disease Subtypes Secondary myelofibrosis (post-PV/post-ET MF) 35
Symptom Management Atypical EMH mass-related symptoms (dyspnea, ascites, pain) in MF 2
Symptom Management Bone pain 2
Symptom Management Constitutional fever (low-grade / FUO-like) 8
Symptom Management Hyperviscosity encephalopathy 1
Symptom Management IgA nephropathy in MPN 1
Symptom Management Lysozyme-associated nephropathy (renal complications in MPN) 2
Symptom Management Mucositis (transplant-related) 3
Symptom Management Pulmonary hypertension and right ventricular dysfunction 1
Symptom Management Splanchnic venous thrombosis 11
Symptom Management Splenic artery aneurysm (MF-associated) 1
Symptom Management Thoracic aortic aneurysm (JAK2-associated) 1
Stem Cell Transplant Decisions Allogeneic HCT in MDS/MPN with neutrophilia 1
Stem Cell Transplant Decisions Atypical extramedullary hematopoiesis as an early-transplant referral trigger in MF 1
Stem Cell Transplant Decisions CALR-mutated MPN outcome heterogeneity from HMR co-mutations 1
Stem Cell Transplant Decisions CALR-targeted therapies and the MF transplant paradigm 2
Stem Cell Transplant Decisions CD24Fc for GVHD prevention in MPN allo-HSCT 1
Stem Cell Transplant Decisions CD8-reduced T cells for MDS/AML transformation of MPN 1
Stem Cell Transplant Decisions CLAG-M or FLAG-Ida + TBI reduced-intensity conditioning 1
Stem Cell Transplant Decisions Clofarabine + Melphalan conditioning regimen 1
Stem Cell Transplant Decisions Decitabine + FLAG-Ida + TBI conditioning for high-risk myeloid malignancies 1
Stem Cell Transplant Decisions FLAMSA + Treosulfan + Venetoclax conditioning (FLAMSAClax) 1
Stem Cell Transplant Decisions Fludarabine + Busulfan conditioning regimen 2
Stem Cell Transplant Decisions Hyperbaric oxygen therapy peri-allo-HSCT 1
Stem Cell Transplant Decisions MRD-guided post-transplant maintenance assignment 1
Stem Cell Transplant Decisions MYSEC-PM scoring (secondary MF) 2
Stem Cell Transplant Decisions MYSEC-mPM / MYSEC-kmPM (molecular/karyotype-augmented MYSEC-PM) 1
Stem Cell Transplant Decisions Post-transplant pegylated interferon alfa-2a maintenance in myelofibrosis 1
Stem Cell Transplant Decisions Pretransplant splenomegaly debulking in myelofibrosis 1
Stem Cell Transplant Decisions Reduced-intensity haploidentical HCT in myelofibrosis 3
Stem Cell Transplant Decisions TP53 mutation status as a transplant-decision modifier in Ph-negative MPN 2
Stem Cell Transplant Decisions Tagraxofusp post-transplant maintenance (CD123+ MF/CMML/AML/MDS) 1
Stem Cell Transplant Decisions Thiotepa/busulfan/fludarabine conditioning for CMML allo-HSCT 1
Stem Cell Transplant Decisions Transplant underuse in intermediate-2/high-risk myelofibrosis 10
Stem Cell Transplant Decisions iCasp9 suicide-gene allodepleted donor T cells (CASPALLO) 1
Treatments AG-236 1
Treatments ASTX727 + Venetoclax combination (CMML / MDS-MPN) 6
Treatments Abemaciclib + Ruxolitinib combination 1
Treatments Anti-MPL neutralizing antibody 1
Treatments Asciminib 1
Treatments Ascorbic acid plus combination chemotherapy (CMML/CCUS) 1
Treatments Aspirin (antiplatelet) 1
Treatments Aspirin in MPN 1
Treatments Axatilimab (CSF1R monoclonal antibody) 1
Treatments Azacitidine 1
Treatments Azacitidine (5-AZA) 4
Treatments Azacitidine + Pacritinib (CMML) 1
Treatments Azacitidine + Ruxolitinib combination 2
Treatments Azacitidine ± Lenalidomide or Vorinostat (higher-risk MDS/CMML) 1
Treatments BEBT-507 1
Treatments BMS-986158 (BET bromodomain inhibitor) 1
Treatments Bezuclastinib (CGT9486) 1
Treatments Busulfan 1
Treatments CALR peptide vaccines 1
Treatments CALR-directed antibody-drug conjugates 1
Treatments CALR-directed bispecific T-cell engagers 1
Treatments CD24Fc (GVHD prevention in MPN transplant) 1
Treatments CD4CAR T-cell therapy (CD4-directed chimeric antigen receptor T cells) 1
Treatments CD8-reduced T cells for MDS/AML in MPN progression 1
Treatments CIML NK cell therapy for post-transplant MPN relapse 1
Treatments CK0804 (investigational cell therapy for myelofibrosis) 1
Treatments CLAG-M or FLAG-Ida + TBI reduced-intensity conditioning 1
Treatments Canakinumab 1
Treatments Cladribine + Low-dose Cytarabine + Venetoclax alternating with Azacitidine + Venetoclax (higher-risk CMML/MDS) 1
Treatments Clofarabine + Melphalan conditioning regimen 1
Treatments Clopidogrel in Essential Thrombocythemia 1
Treatments Conditioning regimen comparison: FluBu vs FluBu+TBI in myeloid malignancies 1
Treatments Cytokine-induced memory-like (CIML) NK cells in myeloid malignancies 1
Treatments DMR-001 (mutant CALR-targeted antibody) 1
Treatments Dasatinib 1
Treatments Decitabine 1
Treatments Decitabine + FLAG-Ida + TBI conditioning regimen 1
Treatments Deucravacitinib (TYK2 inhibitor in MPN) 1
Treatments Direct oral anticoagulants (DOACs) in MPN thrombosis 1
Treatments E7820 (splicing factor inhibitor) 1
Treatments Elotuzumab (anti-SLAMF7 monoclonal antibody) in myelofibrosis 1
Treatments Elritercept (MF anemia) 1
Treatments Eltrombopag (TET2-mutant low-risk MDS/CMML) 1
Treatments Emavusertib 1
Treatments Epitranscriptomic (m6A) pathway inhibitors in MPN 1
Treatments FL118 (DDX5 protein degrader) 1
Treatments Ferroptosis-based treatment strategies 1
Treatments Flonoltinib maleate 3
Treatments Galectin-1 inhibition (novel therapeutic target in MPN) 1
Treatments Gecacitinib 1
Treatments Hyperbaric Oxygen Therapy (peri-transplant) 1
Treatments INCB000928 (investigational agent for MF-related anemia) 1
Treatments Imatinib 1
Treatments Imetelstat (telomerase inhibitor for MPN) 1
Treatments Imetelstat (telomerase inhibitor) 1
Treatments Intensive 7+3 induction for secondary/blast-phase AML 1
Treatments Interferon-α 1
Treatments Interferon-α (cytoreduction in MPN) 1
Treatments Interferon-α mechanism of action in MPN 1
Treatments JBI-802 (investigational oral agent for MPN/MDS-MPN with thrombocytosis) 1
Treatments LP-108 + Azacitidine combination 1
Treatments LY2784544 (JAK2 inhibitor) 1
Treatments Low-dose aspirin 1
Treatments Low-dose aspirin in Essential Thrombocythemia 1
Treatments Low-dose splenic irradiation (pretransplant MF) 1
Treatments Low-molecular-weight heparin (LMWH) 1
Treatments Luspatercept (ACE-536) 1
Treatments Lustracept (MF-associated anemia) 1
Treatments Metronomic ASTX727 + Venetoclax (R/R AML, HR-MDS, HR/AP MPN) 1
Treatments Mutant CALR BiTEs and antibody-drug conjugates 1
Treatments Mutant CALR CAR-T cells 1
Treatments Mutant CALR peptide vaccine 2
Treatments Mutant CALR peptide vaccine (MPN immunotherapy) 1
Treatments Mutant CALR-directed immunotherapy 1
Treatments Mutant CALR-specific monoclonal antibodies 1
Treatments Navtemadlin (MDM2 antagonist) 1
Treatments Navtemadlin (MDM2 inhibitor) 1
Treatments Olutasidenib + Hypomethylating Agent combination 1
Treatments PIM kinase inhibitors (MPN) 1
Treatments PRT12396 (JAK2V617F mutant-selective JH2 inhibitor) 1
Treatments PRT12396 (mutant-selective JAK2V617F inhibitor) 1
Treatments PRT12396 (mutant-selective JAK2V617F inhibitor) 1
Treatments PXS-5505 (pan-LOX/LOXL inhibitor) 1
Treatments Pacritinib + Venetoclax + Azacitidine combination (AP/BP MPN) 1
Treatments Palliative hepatosplenic radiotherapy for EMH 1
Treatments Pegylated interferon alfa-2a 1
Treatments Pelabresib (BET bromodomain inhibitor) 8
Treatments Pharmacological C3 complement inhibition (myelofibrosis) 1
Treatments Phlebotomy-only maintenance in PV 20
Treatments Pitavastatin (antifibrotic in JAK2V617F MF) 1
Treatments Post-transplant HMA maintenance (oral decitabine/cedazuridine) 1
Treatments RAD001 (Everolimus, mTOR inhibitor) 1
Treatments RPG4 (CALR-directed CAR T-cell therapy) 1
Treatments RVU120 (investigational agent for MF) 1
Treatments Radiotherapy for extramedullary hematopoiesis in MF 1
Treatments Rebecsinib (investigational agent for high-risk MF / sAML) 1
Treatments Recombinant EphB4-HSA fusion protein + HMA (azacitidine or decitabine) 1
Treatments Reduced-intensity haploidentical HCT (myelofibrosis) 1
Treatments Revumenib (menin inhibitor) 1
Treatments Rusfertide (hepcidin mimetic for PV) 1
Treatments Rusfertide (hepcidin mimetic) 8
Treatments Ruxolitinib in Chronic Myelomonocytic Leukemia (CMML) 1
Treatments Sapablursen (TMPRSS6 antisense oligonucleotide) 1
Treatments Selcodebart 1
Treatments Selinexor + Azacitidine combination 1
Treatments Selinexor combination therapy in MDS/MPN overlap syndromes 1
Treatments Selinexor monotherapy (JAKi-refractory/intolerant myelofibrosis) 1
Treatments Selinexor monotherapy (cytoreduction in BCR::ABL1-negative MPN) 1
Treatments Sosimerasib Sulfate Tablets (Jilemei) 1
Treatments Splenectomy for EMH-related complications in MF 1
Treatments TCR-based immunotherapy for MPN 1
Treatments TGR-1202 (PI3K-delta inhibitor) + Ruxolitinib combination 1
Treatments TP-3654 (PIM kinase inhibitor) 1
Treatments TPO/MPL pathway-targeted therapy 1
Treatments TQ05105 (JAK2 inhibitor) 2
Treatments Tagraxofusp (CD123-directed post-HCT maintenance) 1
Treatments Thiotepa + Busulfan + Fludarabine (± ATG) conditioning regimen (CMML) 1
Treatments Trametinib 2
Treatments Trametinib + Azacitidine (JMML) 1
Treatments UBP310/UBP296 (mGluR5 inhibitors) 1
Treatments Ulixertinib + Ruxolitinib combination (ERK1/2 + JAK inhibition in myelofibrosis) 1
Treatments Venetoclax + FLAMSA + Treosulfan conditioning (FLAMSAClax) 1
Treatments Venetoclax + Fludarabine/Busulfan conditioning + post-transplant maintenance 1
Treatments Zavabresib (OPN-2853, selective BET inhibitor) 1
Treatments iCasp9-transduced allodepleted T cells (CASPALLO) 1

Dynamic queries this run

SPEC-V2.4 — the expander proposes new searches for pages that have crossed their mention threshold. They run on subsequent scans alongside the static spec queries.

Metric Count
New queries proposed 101
Active queries that fired 80
Items pulled in via dynamic queries 133
Queries auto-demoted this run 19

Proposed this run

PageSourceQueryRationaleStatus
Bone marrow fibrosis pubmed ("SLAMF7"[Title/Abstract] OR elotuzumab[Title/Abstract] OR "anti-SLAMF7"[Title/Abstract] OR CD319[Title/Abstract]) AND (fibrocyte[Title/Abstract] OR fibrocytes[Title/Abstract] OR "bone marrow fibrosis"[Title/Abstract] OR "marrow fibrosis"[Title/Abstract] OR myelofibrosis[Title/Abstract] OR "collagen-producing"[Title/Abstract] OR "collagen deposition"[Title/Abstract]) Catches SLAMF7/elotuzumab immunotherapy evidence on fibrocytes and marrow fibrosis in MPN or adjacent settings, which no existing query covers. active
Inflammatory cytokine signaling pubmed "ruxolitinib"[Title/Abstract] AND (pruritus[Title/Abstract] OR itch[Title/Abstract] OR itching[Title/Abstract] OR aquagenic[Title/Abstract]) AND (myelofibrosis[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR myeloproliferative[Title/Abstract] OR MPN[Title/Abstract] OR "IL-6"[Title/Abstract] OR TNF[Title/Abstract] OR cytokine[Title/Abstract] OR JAK[Title/Abstract]) Pairs ruxolitinib specifically with pruritus/itch endpoints and cytokine/JAK context to catch confirming or disconfirming symptom-response evidence not covered by broader ruxolitinib, night-sweat, or IL-6/TNF queries. active
JAK-STAT signaling pubmed ("ropeginterferon"[Title/Abstract] OR Besremi[Title/Abstract] OR "ropeginterferon alfa-2b"[Title/Abstract]) AND (microvascular[Title/Abstract] OR erythromelalgia[Title/Abstract] OR "symptom burden"[Title/Abstract] OR "MPN-SAF"[Title/Abstract] OR pruritus[Title/Abstract] OR headache[Title/Abstract]) AND ("allele burden"[Title/Abstract] OR "JAK-STAT"[Title/Abstract] OR "molecular response"[Title/Abstract] OR "variant allele frequency"[Title/Abstract] OR pSTAT[Title/Abstract]) Links ropeginterferon/Besremi specifically to microvascular or symptom outcomes plus allele-burden/JAK-STAT readouts, catching confirming or disconfirming evidence for the hypothesis without duplicating the broader ropeginterferon, peg-IFN, or CHIP-constrained queries. active
Clonal hematopoiesis pubmed "INCA033989"[Title/Abstract] AND ("clonal hematopoiesis"[Title/Abstract] OR CHIP[Title/Abstract] OR "clonal haematopoiesis"[Title/Abstract] OR "allele burden"[Title/Abstract] OR "variant allele frequency"[Title/Abstract] OR "mutant clone"[Title/Abstract] OR "clonal depletion"[Title/Abstract] OR "selective depletion"[Title/Abstract] OR "clone reduction"[Title/Abstract]) Existing INCA033989 queries cover disease labels and splenomegaly/signaling but miss clonal-dynamics endpoints (CHIP, allele burden, mutant-clone depletion) that would confirm or refute the selective mutant-CALR CH mechanism. active
Bone marrow fibrosis pubmed ("elritercept"[Title/Abstract] OR "KER-050"[Title/Abstract] OR "KER050"[Title/Abstract]) AND (myelofibrosis[Title/Abstract] OR "bone marrow fibrosis"[Title/Abstract] OR myeloproliferative[Title/Abstract] OR MDS[Title/Abstract] OR myelodysplastic[Title/Abstract] OR "TGF-beta"[Title/Abstract] OR "TGF-β"[Title/Abstract] OR activin[Title/Abstract] OR "ligand trap"[Title/Abstract] OR ActRII[Title/Abstract]) No existing query covers elritercept/KER-050; this catches confirming or disproving evidence on its TGF-β superfamily ligand-trap effects on marrow fibrosis in MF and adjacent MDS/anemia contexts. active
Inflammatory cytokine signaling pubmed ("BET inhibitor"[Title/Abstract] OR "BET bromodomain"[Title/Abstract] OR bromodomain[Title/Abstract]) AND ("NF-κB"[Title/Abstract] OR "NF-kappaB"[Title/Abstract] OR "NF-kB"[Title/Abstract]) AND ("IL-6"[Title/Abstract] OR "interleukin-6"[Title/Abstract] OR "TNF"[Title/Abstract] OR "tumor necrosis factor"[Title/Abstract] OR "night sweats"[Title/Abstract] OR cytokine[Title/Abstract]) Catches BET–NF-κB–IL-6/TNF/night-sweat mechanism papers in any population, which existing pelabresib-only, MPN-restricted cytokine/NF-κB, and BET+MPN queries do not cover. active
JAK-STAT signaling pubmed "ruxolitinib"[Title/Abstract] AND ("night sweats"[Title/Abstract] OR "night sweat"[Title/Abstract] OR diaphoresis[Title/Abstract] OR "constitutional symptoms"[Title/Abstract] OR "symptom response"[Title/Abstract]) AND (myelofibrosis[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR myeloproliferative[Title/Abstract] OR MPN[Title/Abstract] OR cytokine[Title/Abstract]) Targets ruxolitinib effects on night sweats/constitutional symptoms (confirming or disproving the hypothesis) which no existing ruxolitinib, cytokine, or JAK-STAT query isolates. active
Clonal hematopoiesis pubmed ("canakinumab"[Title/Abstract] OR anakinra[Title/Abstract]) AND ("clonal hematopoiesis"[Title/Abstract] OR CHIP[Title/Abstract] OR "clonal haematopoiesis"[Title/Abstract]) AND (microvascular[Title/Abstract] OR erythromelalgia[Title/Abstract] OR CANTOS[Title/Abstract] OR cardiovascular[Title/Abstract] OR "clonal expansion"[Title/Abstract] OR "clonal fitness"[Title/Abstract] OR endothelial[Title/Abstract]) Targets canakinumab/anakinra specifically with CHIP plus microvascular, clonal-fitness, or CANTOS/cardiovascular endpoints, catching confirming or disproving evidence in MPN and adjacent CHIP populations not covered by the existing fatigue/IL-1×MPN/CHIP or CHIP×JAK2×microvascular queries. active
Thrombosis risk pubmed ("bomedemstat"[Title/Abstract] OR "IMG-7289"[Title/Abstract] OR "MK-3543"[Title/Abstract] OR "LSD1 inhibitor"[Title/Abstract] OR "LSD1 inhibition"[Title/Abstract]) AND ("thrombosis"[Title/Abstract] OR "thrombotic"[Title/Abstract] OR "thromboembolic"[Title/Abstract] OR "platelet mass"[Title/Abstract] OR "platelet count"[Title/Abstract] OR "arterial thrombosis"[Title/Abstract] OR "venous thrombosis"[Title/Abstract]) Links bomedemstat/LSD1 to thrombosis and platelet-mass endpoints (confirming or disproving) without requiring MPN disease terms already covered by existing bomedemstat queries. active
Bone marrow fibrosis pubmed "pitavastatin"[Title/Abstract] AND (fibrosis[Title/Abstract] OR fibrocyte[Title/Abstract] OR fibrocytes[Title/Abstract] OR "TGF-beta"[Title/Abstract] OR "TGF-β"[Title/Abstract] OR "TGF-β1"[Title/Abstract] OR myelofibrosis[Title/Abstract] OR "marrow fibrosis"[Title/Abstract] OR "bone marrow"[Title/Abstract]) Targets pitavastatin specifically with fibrosis/fibrocyte/TGF-β endpoints across MPN and adjacent contexts, catching confirming or disconfirming evidence not covered by any existing statin-free or broad fibrosis queries. active
Inflammatory cytokine signaling pubmed pacritinib[Title/Abstract] AND (fatigue[Title/Abstract] OR "symptom burden"[Title/Abstract] OR MyD88[Title/Abstract] OR "IL-1"[Title/Abstract] OR "IL-6"[Title/Abstract] OR IRAK1[Title/Abstract]) AND (myelofibrosis[Title/Abstract] OR myeloproliferative[Title/Abstract] OR MPN[Title/Abstract] OR cytokine[Title/Abstract]) Targets pacritinib’s JAK2/IRAK1–MyD88–IL-1/IL-6 axis and fatigue/symptom outcomes beyond the existing pacritinib OR myelofibrosis/thrombocytopenia/IRAK1 query, catching confirming or disconfirming evidence. active
ASTX727 (oral cedazuridine + decitabine) pubmed ("ASTX727"[Title/Abstract] OR cedazuridine[Title/Abstract] OR Inqovi[Title/Abstract] OR "decitabine-cedazuridine"[Title/Abstract] OR "decitabine cedazuridine"[Title/Abstract]) AND (myeloproliferative[Title/Abstract] OR myelofibrosis[Title/Abstract] OR MPN[Title/Abstract] OR MDS[Title/Abstract] OR CMML[Title/Abstract] OR "myelodysplastic"[Title/Abstract] OR AML[Title/Abstract] OR "chronic myelomonocytic"[Title/Abstract]) Targets the oral cedazuridine/decitabine fixed-dose product (ASTX727/Inqovi) by name, which existing decitabine/azacitidine and hypomethylating-agent queries do not specifically cover. active
Azacitidine + Venetoclax + Gilteritinib combination pubmed "gilteritinib"[Title/Abstract] AND "venetoclax"[Title/Abstract] AND ("azacitidine"[Title/Abstract] OR azacytidine[Title/Abstract] OR "5-AZA"[Title/Abstract]) AND (FLT3[Title/Abstract] OR AML[Title/Abstract] OR MDS[Title/Abstract] OR CMML[Title/Abstract] OR "MDS/MPN"[Title/Abstract] OR myeloproliferative[Title/Abstract]) Targets the specific Aza+Ven+Gilt triplet and FLT3/MDS-MPN context; existing queries cover azacitidine broadly or other agents but none combine gilteritinib with venetoclax and a hypomethylating agent. active
Fedratinib pubmed ("Inrebic"[Title/Abstract] OR "SAR302503"[Title/Abstract] OR "TG101348"[Title/Abstract]) AND (myelofibrosis[Title/Abstract] OR "myeloproliferative"[Title/Abstract] OR MPN[Title/Abstract] OR "JAK2"[Title/Abstract]) Existing fedratinib query only matches the generic name; this catches brand and legacy code names (Inrebic/SAR302503/TG101348) used in older or label-focused MPN literature that would otherwise be missed. active
XPO1 nuclear export pubmed ("XPO1"[Title/Abstract] OR "exportin-1"[Title/Abstract] OR "exportin 1"[Title/Abstract] OR selinexor[Title/Abstract]) AND (myelofibrosis[Title/Abstract] OR "myeloproliferative"[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract]) Catches XPO1/exportin-1 mechanism and selinexor monotherapy or non-ruxolitinib combination papers in MPN that the existing selinexor+ruxolitinib-only query misses. active
Mutant-selective JAK2V617F inhibition via JH2 pseudokinase domain pubmed "PRT12396"[Title/Abstract] OR (("JH2"[Title/Abstract] OR "pseudokinase domain"[Title/Abstract]) AND "JAK2"[Title/Abstract] AND (allosteric[Title/Abstract] OR "mutant-selective"[Title/Abstract] OR inhibitor[Title/Abstract]) AND (myeloproliferative[Title/Abstract] OR myelofibrosis[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "V617F"[Title/Abstract])) Retrieves JH2/pseudokinase-directed and mutant-selective JAK2V617F inhibitor papers (including PRT12396) that broad JAK2 V617F, JAK-STAT, pan-JAK, and type II JH1 queries do not specifically cover. active
MPL mutations pubmed ("thrombopoietin receptor"[Title/Abstract] OR "TPO-R"[Title/Abstract] OR "c-MPL"[Title/Abstract]) AND (W515[Title/Abstract] OR S505N[Title/Abstract] OR "exon 10"[Title/Abstract] OR "activating mutation"[Title/Abstract]) AND ("essential thrombocythemia" OR myelofibrosis OR myeloproliferative) Catches TPO-R/c-MPL nomenclature and non-W515L/K variants (S505N, exon 10, other W515) without requiring the gene symbol MPL, which the existing MPL-focused dynamic query always mandates. active
Clonal hematopoiesis pubmed ("bomedemstat"[Title/Abstract] OR "IMG-7289"[Title/Abstract] OR "MK-3543"[Title/Abstract] OR "LSD1 inhibitor"[Title/Abstract] OR "LSD1 inhibition"[Title/Abstract]) AND ("clonal hematopoiesis"[Title/Abstract] OR CHIP[Title/Abstract] OR splenomegaly[Title/Abstract] OR "spleen volume"[Title/Abstract] OR "allele burden"[Title/Abstract] OR "clonal fitness"[Title/Abstract] OR "mutant clone"[Title/Abstract]) Targets bomedemstat/LSD1 inhibition linked to splenomegaly and clonal fitness endpoints, including non-MPN CHIP/myeloid contexts the existing MPN-only bomedemstat query misses. active
Inflammatory cytokine signaling pubmed ("NK cell"[Title/Abstract] OR "NK cells"[Title/Abstract] OR "natural killer"[Title/Abstract]) AND (interferon[Title/Abstract] OR ropeginterferon[Title/Abstract] OR "type-I interferon"[Title/Abstract] OR "type I interferon"[Title/Abstract]) AND ("polycythemia vera"[Title/Abstract] OR myelofibrosis[Title/Abstract] OR myeloproliferative[Title/Abstract] OR JAK2[Title/Abstract] OR fatigue[Title/Abstract]) Targets the IFN–NK clone-clearance mechanism and fatigue link for ropeginterferon that existing ropeginterferon, cytokine, and QoL queries do not specifically cover. active
JAK-STAT signaling pubmed "INCA033989"[Title/Abstract] AND ("splenomegaly"[Title/Abstract] OR "spleen volume"[Title/Abstract] OR "spleen size"[Title/Abstract] OR "spleen response"[Title/Abstract] OR "JAK-STAT"[Title/Abstract] OR pSTAT5[Title/Abstract] OR MPL[Title/Abstract]) Targets INCA033989 with splenomegaly and CALR–MPL–JAK-STAT mechanism/readout terms rather than disease labels, catching confirming or disconfirming spleen and pathway evidence in adjacent models the existing drug+MPN query can miss. active
Diet and Nutrition pubmed ("Mediterranean diet"[Title/Abstract] OR "anti-inflammatory diet"[Title/Abstract] OR "dietary pattern"[Title/Abstract] OR "nutritional intervention"[Title/Abstract] OR "dietary iron"[Title/Abstract] OR "iron intake"[Title/Abstract] OR nutrition[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR myelofibrosis[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract] OR MPN[Title/Abstract]) Catches diet-pattern, Mediterranean/anti-inflammatory nutrition, and dietary iron literature for MPNs not covered by the existing supplement/antioxidant or hepcidin-pathway queries. active
Azacitidine (5-AZA) pubmed ("azacitidine"[Title/Abstract] OR "5-azacitidine"[Title/Abstract] OR "5-AZA"[Title/Abstract] OR Vidaza[Title/Abstract]) AND (myeloproliferative[Title/Abstract] OR myelofibrosis[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract] OR CMML[Title/Abstract] OR "chronic myelomonocytic"[Title/Abstract] OR "MDS/MPN"[Title/Abstract] OR JMML[Title/Abstract]) Targets azacitidine/5-AZA/Vidaza specifically (not the broader epigenetic/decitabine bundle already running) and adds CMML, JMML, and MDS/MPN overlap terms that match tagged findings and are missing from the existing azacitidine-containing query. active
Fludarabine + Busulfan conditioning regimen pubmed ("fludarabine"[Title/Abstract] AND "busulfan"[Title/Abstract]) AND (conditioning[Title/Abstract] OR "reduced-intensity"[Title/Abstract] OR RIC[Title/Abstract] OR "stem cell transplantation"[Title/Abstract]) AND (myelofibrosis[Title/Abstract] OR "myeloproliferative"[Title/Abstract] OR MPN[Title/Abstract] OR "polycythemia vera"[Title/Abstract]) Targets fludarabine/busulfan conditioning specifically for MPN allotransplant, which no existing static or dynamic query covers. active
INCA033989 (novel investigational agent for MPN) pubmed INCA033989[Title/Abstract] AND (myeloproliferative OR myelofibrosis OR "essential thrombocythemia" OR MPN OR CALR) Targets the specific investigational agent INCA033989 by name, which no existing static or dynamic query covers, while broader mutant-CALR queries miss drug-specific papers. active
Inflammatory cytokine signaling pubmed ("NLRP3"[Title/Abstract] OR inflammasome[Title/Abstract] OR "interleukin-1"[Title/Abstract] OR "IL-1beta"[Title/Abstract] OR "IL-1β"[Title/Abstract] OR "NF-kappaB"[Title/Abstract] OR "NF-κB"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR myelofibrosis[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract]) Captures upstream inflammasome/IL-1/NF-κB inflammatory signaling in MPN that existing IL-6/IL-8/TNF and drug-tied canakinumab/anakinra queries miss. active
CALR mutations pubmed ("mutant calreticulin"[Title/Abstract] OR "mutant CALR"[Title/Abstract] OR "CALR-directed"[Title/Abstract] OR "anti-CALR"[Title/Abstract] OR "CALR neoantigen"[Title/Abstract]) AND (myeloproliferative OR myelofibrosis OR "essential thrombocythemia" OR MPN) Pulls mutant-CALR biology and CALR-directed/immunotherapy papers in MPN without requiring exon-9/type-1/type-2/MPL terms already used by the existing CALR dynamic query. active
JAK-STAT signaling pubmed ("STAT5"[Title/Abstract] OR "STAT3"[Title/Abstract] OR pSTAT5[Title/Abstract] OR "STAT phosphorylation"[Title/Abstract]) AND ("JAK2"[Title/Abstract] OR "Janus kinase"[Title/Abstract]) AND (myeloproliferative[Title/Abstract] OR myelofibrosis[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract]) Catches STAT3/STAT5-centric JAK2 pathway mechanism papers that omit the exact phrase JAK-STAT already covered by the existing dynamic query. active
Clonal hematopoiesis pubmed ("clonal hematopoiesis"[Title/Abstract] OR "CHIP"[Title/Abstract] OR "clonal haematopoiesis"[Title/Abstract]) AND "JAK2"[Title/Abstract] AND (ropeginterferon[Title/Abstract] OR interferon[Title/Abstract] OR microvascular[Title/Abstract] OR "symptom burden"[Title/Abstract] OR "allele burden"[Title/Abstract] OR Besremi[Title/Abstract]) Catches JAK2-mutant CHIP/CH papers tied to interferon or microvascular/symptom/allele-burden endpoints that existing TET2/DNMT3A/ASXL1-CHIP and broad ropeginterferon queries miss. active
Thrombosis risk pubmed ("rusfertide"[Title/Abstract] OR "PTG-300"[Title/Abstract] OR "hepcidin mimetic"[Title/Abstract]) AND ("thrombosis"[Title/Abstract] OR "thrombotic"[Title/Abstract] OR "thromboembolic"[Title/Abstract] OR "arterial"[Title/Abstract] OR "venous thromboembolism"[Title/Abstract] OR "hematocrit"[Title/Abstract] OR "cardiovascular event"[Title/Abstract]) Targets rusfertide/PTG-300 specifically with thrombosis and Hct-control outcome terms, catching confirming or disconfirming evidence beyond the broader hepcidin-axis + MPN query that lacks thrombotic endpoints. active
Bone marrow fibrosis pubmed ("C3"[Title/Abstract] OR "complement C3"[Title/Abstract] OR "C3 inhibitor"[Title/Abstract] OR "complement inhibition"[Title/Abstract] OR pegcetacoplan[Title/Abstract] OR "anti-C3"[Title/Abstract]) AND (myelofibrosis[Title/Abstract] OR "myeloproliferative"[Title/Abstract] OR "bone marrow fibrosis"[Title/Abstract]) AND (splenomegaly[Title/Abstract] OR spleen[Title/Abstract] OR stromal[Title/Abstract] OR "pro-fibrotic"[Title/Abstract] OR fibrosis[Title/Abstract]) Targets C3/complement inhibition evidence for or against reduced splenomegaly and pro-fibrotic stromal effects in MPN/fibrosis, a niche not covered by existing cytokine, JAK, or generic fibrosis queries. active
Inflammatory cytokine signaling pubmed ("canakinumab"[Title/Abstract] OR anakinra[Title/Abstract]) AND (fatigue[Title/Abstract] OR "IL-1 beta"[Title/Abstract] OR "interleukin-1 beta"[Title/Abstract] OR "IL-1β"[Title/Abstract]) AND (myeloproliferative[Title/Abstract] OR myelofibrosis[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract] OR MPN[Title/Abstract] OR CHIP[Title/Abstract]) Targets canakinumab/anakinra IL-1β blockade linked to fatigue or IL-1β in MPN/CHIP populations, catching confirming or disconfirming evidence absent from existing IL-6/TNF and drug-specific queries. active
Exercise and Physical Activity pubmed ("exercise"[Title/Abstract] OR "physical activity"[Title/Abstract] OR "exercise training"[Title/Abstract] OR "aerobic exercise"[Title/Abstract] OR "resistance training"[Title/Abstract] OR "exercise program"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "myelofibrosis"[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract] OR MPN[Title/Abstract]) Retrieves MPN-specific exercise and physical-activity intervention studies (e.g., fatigue, fitness programs) not covered by existing diet, supplement, thrombosis, or psychosocial lifestyle queries. active
Bomedemstat pubmed ("bomedemstat"[Title/Abstract] OR "IMG-7289"[Title/Abstract] OR "MK-3543"[Title/Abstract]) AND (myeloproliferative[Title/Abstract] OR myelofibrosis[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract] OR MPN[Title/Abstract]) Captures bomedemstat and its development codes in MPN contexts, which no existing static or dynamic query covers. active
Fedratinib pubmed "fedratinib"[Title/Abstract] AND (myelofibrosis[Title/Abstract] OR "myeloproliferative"[Title/Abstract] OR "ruxolitinib"[Title/Abstract] OR JAKARTA[Title/Abstract] OR "JAK2"[Title/Abstract]) No existing query targets fedratinib itself; this pulls MF/MPN and ruxolitinib-failure/JAKARTA literature on this selective JAK2 inhibitor without overlapping ruxolitinib- or pacritinib-only searches. active
Pacritinib pubmed "pacritinib"[Title/Abstract] AND (myelofibrosis[Title/Abstract] OR "myeloproliferative"[Title/Abstract] OR thrombocytopenia[Title/Abstract] OR IRAK1[Title/Abstract]) No existing query targets pacritinib itself; this pulls MF/MPN and thrombocytopenia/IRAK1-focused papers on the drug beyond incidental co-mentions in broad JAK-inhibitor comparisons. active
ACVR1 signaling and hepcidin axis pubmed ("ACVR1"[Title/Abstract] OR "ALK2"[Title/Abstract] OR hepcidin[Title/Abstract] OR ferroportin[Title/Abstract] OR momelotinib[Title/Abstract] OR rusfertide[Title/Abstract] OR BMP6[Title/Abstract]) AND (myelofibrosis[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR myeloproliferative[Title/Abstract]) Pulls ACVR1/ALK2–BMP6–hepcidin–ferroportin axis and ACVR1-inhibitor/hepcidin-targeted agents (momelotinib, rusfertide) in MPN that no existing static or dynamic query covers. active
Blast-phase MPN and leukemic transformation pubmed ("blast phase"[Title/Abstract] OR "blast-phase"[Title/Abstract] OR "MPN-BP"[Title/Abstract] OR "leukemic transformation"[Title/Abstract] OR "leukaemic transformation"[Title/Abstract]) AND (myeloproliferative[Title/Abstract] OR myelofibrosis[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract]) Targets blast-phase MPN and leukemic transformation specifically—terms absent from existing static and dynamic queries—capturing progression-to-AML mechanisms and mutational context without overlapping broader MPN or cytokine/JAK coverage. active
Bone marrow fibrosis pubmed ("megakaryocyte"[Title/Abstract] OR "megakaryocytes"[Title/Abstract] OR "megakaryopoiesis"[Title/Abstract]) AND ("bone marrow fibrosis"[Title/Abstract] OR "marrow fibrosis"[Title/Abstract] OR "collagen deposition"[Title/Abstract] OR reticulin[Title/Abstract] OR fibrocyte[Title/Abstract]) AND (myelofibrosis[Title/Abstract] OR myeloproliferative[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract] OR "polycythemia vera"[Title/Abstract]) Catches megakaryocyte- and fibrocyte-driven marrow fibrosis mechanisms that the existing bone-marrow-fibrosis plus TGF-beta/reticulin query does not specifically target. active
Stress and Psychological Factors pubmed ("psychological stress"[Title/Abstract] OR "anxiety"[Title/Abstract] OR "depression"[Title/Abstract] OR "mindfulness"[Title/Abstract] OR "mind-body"[Title/Abstract] OR "quality of life"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "myelofibrosis"[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract]) Targets psychological/stress/QoL interventions in MPN patients, a dimension not covered by any existing query which focus on cytokines, treatments, mutations, or dietary factors. active
ASTX727 (oral cedazuridine + decitabine) pubmed ("ASTX727"[Title/Abstract] OR "cedazuridine"[Title/Abstract] OR "oral decitabine"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "MPN"[Title/Abstract] OR "myelofibrosis"[Title/Abstract] OR "CMML"[Title/Abstract] OR "MDS/MPN"[Title/Abstract]) AND ("pharmacokinetics"[Title/Abstract] OR "bioavailability"[Title/Abstract] OR "clinical trial"[Title/Abstract] OR "phase"[Title/Abstract] OR "response"[Title/Abstract]) Existing dynamic queries for ASTX727 require co-occurrence with venetoclax or iadademstat/LSD1/decitabine; this query captures standalone ASTX727/cedazuridine clinical and pharmacokinetic studies in MPN/CMML contexts not covered by those constraints. demoted
AJ1-11095 (Type II JAK2 inhibitor) pubmed "AJ1-11095"[Title/Abstract] OR ("type II JAK2 inhibitor"[Title/Abstract] AND ("myelofibrosis"[Title/Abstract] OR "myeloproliferative"[Title/Abstract])) Targets AJ1-11095 specifically and the novel type II JAK2 inhibitor mechanism class, neither of which is covered by any existing query. active
ASTX727 + Venetoclax combination (CMML / MDS-MPN) pubmed "venetoclax"[Title/Abstract] AND ("CMML"[Title/Abstract] OR "chronic myelomonocytic leukemia"[Title/Abstract] OR "MDS/MPN"[Title/Abstract]) AND ("BCL-2"[Title/Abstract] OR "BCL2"[Title/Abstract]) AND ("hypomethylating"[Title/Abstract] OR "azacitidine"[Title/Abstract] OR "decitabine"[Title/Abstract]) The existing dynamic query covers ASTX727+venetoclax specifically; this query broadens to capture HMA+venetoclax combination rationale and outcomes literature in CMML/MDS-MPN more generally, including BCL-2 biology context not yet covered. demoted
Inflammatory cytokine signaling pubmed ("inflammatory cytokine"[Title/Abstract] OR "cytokine storm"[Title/Abstract] OR "cytokine profile"[Title/Abstract] OR "proinflammatory"[Title/Abstract]) AND ("constitutional symptoms"[Title/Abstract] OR "fatigue"[Title/Abstract] OR "pruritus"[Title/Abstract] OR "clonal advantage"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "myelofibrosis"[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract]) The existing IL-6/TNF-alpha query covers specific cytokines but misses broader inflammatory cytokine signaling in the context of MPN constitutional symptoms and clonal advantage, which is the core concept of this page. demoted
DNA hypomethylation and epigenetic reprogramming pubmed ("DNA hypomethylation"[Title/Abstract] OR "epigenetic reprogramming"[Title/Abstract] OR "DNMT3A"[Title/Abstract] OR "TET2"[Title/Abstract] OR "azacitidine"[Title/Abstract] OR "decitabine"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "myelofibrosis"[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract]) Targets DNA methylation machinery and hypomethylating agents specifically in MPN context, which existing queries only touch tangentially via CHIP/TET2/DNMT3A in clonal hematopoiesis or azacitidine in blast-phase combinations. active
MPL mutations pubmed "MPL"[Title/Abstract] AND ("W515"[Title/Abstract] OR "S505"[Title/Abstract] OR "Y591"[Title/Abstract] OR "R592"[Title/Abstract] OR "exon 10"[Title/Abstract]) AND ("thrombopoietin receptor"[Title/Abstract] OR "JAK2 activation"[Title/Abstract] OR "signaling"[Title/Abstract]) AND ("essential thrombocythemia" OR "myelofibrosis" OR "myeloproliferative") The existing MPL dynamic query covers W515L/K and general MPL mutations, but this query adds rare/novel MPL variants (S505, Y591, R592, exon 10) and links them to downstream signaling mechanisms, capturing variant-characterization and functional studies not retrieved by the current query. demoted
Diet and Nutrition pubmed ("Mediterranean diet"[Title/Abstract] OR "anti-inflammatory diet"[Title/Abstract] OR "dietary iron"[Title/Abstract] OR "iron intake"[Title/Abstract] OR "nutrition"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "myelofibrosis"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract]) Existing queries cover supplements/antioxidants but not broader dietary patterns (Mediterranean diet, anti-inflammatory diet) or dietary iron management relevant to PV, which are the core of this page's current understanding. demoted
Pelabresib (BET bromodomain inhibitor) pubmed "pelabresib"[Title/Abstract] AND ("ruxolitinib"[Title/Abstract] OR "JAK inhibitor"[Title/Abstract] OR "combination therapy"[Title/Abstract] OR "spleen volume"[Title/Abstract] OR "symptom burden"[Title/Abstract]) AND ("myelofibrosis"[Title/Abstract] OR "myeloproliferative"[Title/Abstract]) The existing query 'pelabresib'[Title/Abstract] OR 'CPI-0610'[Title/Abstract] is broad but lacks context filters; this query targets pelabresib specifically in combination/clinical outcome contexts within MF/MPN, capturing combination trial and efficacy papers not guaranteed by the bare name search. demoted
Phlebotomy-only maintenance in PV pubmed "phlebotomy"[Title/Abstract] AND ("polycythemia vera"[Title/Abstract] OR "polycythaemia vera"[Title/Abstract]) AND ("low-risk"[Title/Abstract] OR "maintenance"[Title/Abstract] OR "watchful waiting"[Title/Abstract] OR "aspirin alone"[Title/Abstract] OR "without cytoreduction"[Title/Abstract]) The existing phlebotomy query focuses on hematocrit/cytoreduction/monotherapy framing; this query targets the phlebotomy-only maintenance concept specifically by adding 'maintenance', 'watchful waiting', and 'without cytoreduction' terms not covered by any existing query. demoted
INCA033989 (novel investigational agent for MPN) pubmed "INCA033989"[Title/Abstract] OR ("anti-CALR"[Title/Abstract] AND "monoclonal antibody"[Title/Abstract] AND ("myeloproliferative"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract] OR "myelofibrosis"[Title/Abstract])) The existing dynamic query covers INCA033989 by title/abstract alone; this expands coverage by also capturing anti-CALR monoclonal antibody papers that may describe INCA033989 without naming it, while the existing mutant-CALR immunotherapy query requires 'immunotherapy OR antibody OR vaccine OR targeted therapy OR neoantigen' and misses papers framed around the antibody mechanism specifically. demoted
Clonal hematopoiesis pubmed ("clonal hematopoiesis"[Title/Abstract] OR "CHIP"[Title/Abstract]) AND ("TET2"[Title/Abstract] OR "DNMT3A"[Title/Abstract] OR "ASXL1"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "myelofibrosis"[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract]) Targets clonal hematopoiesis specifically via co-occurring epigenetic driver mutations (TET2, DNMT3A, ASXL1) in MPN context, which existing queries don't cover — the closest existing query focuses on JAK2/CALR and clonal architecture rather than these CHIP-defining mutations. active
Thrombosis risk pubmed ("cardiovascular risk score"[Title/Abstract] OR "IPSET-thrombosis"[Title/Abstract] OR "thrombotic risk stratification"[Title/Abstract] OR "venous thromboembolism"[Title/Abstract]) AND ("polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract] OR "myeloproliferative"[Title/Abstract]) Targets clinical risk stratification tools and venous thromboembolism specifically in MPN, which the existing thrombosis query covers mechanistically (hematocrit, leukocytosis, allele burden) but not from a scoring/stratification angle. active
JAK-STAT signaling pubmed "JAK-STAT"[Title/Abstract] AND ("myeloproliferative"[Title/Abstract] OR "myelofibrosis"[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract]) AND ("pathway"[Title/Abstract] OR "activation"[Title/Abstract] OR "inhibition"[Title/Abstract] OR "signaling"[Title/Abstract]) Existing queries cover JAK2/STAT3/STAT5 individually or JAK2 V617F specifically, but none target the broader 'JAK-STAT' pathway term as a combined concept in MPN contexts, which would capture mechanistic and review articles framing the pathway holistically. active
Diet and Nutrition pubmed ("curcumin"[Title/Abstract] OR "N-acetylcysteine"[Title/Abstract] OR "antioxidant"[Title/Abstract] OR "omega-3"[Title/Abstract] OR "dietary supplement"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "myelofibrosis"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract]) The existing diet query covers broad dietary/nutritional terms but misses specific nutraceutical/supplement interventions (curcumin, NAC, antioxidants, omega-3) that are directly reflected in the tagged findings and the page's anti-inflammatory focus. active
Hydroxyurea pubmed "hydroxyurea"[MeSH Terms] AND ("polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract] OR "myeloproliferative"[Title/Abstract]) AND ("disease modification"[Title/Abstract] OR "molecular response"[Title/Abstract] OR "thrombosis prevention"[Title/Abstract] OR "cardiovascular risk"[Title/Abstract] OR "long-term"[Title/Abstract]) The existing hydroxyurea dynamic query focuses on resistance/intolerance/cytoreduction/hematocrit; this targets hydroxyurea's long-term outcomes, disease modification potential, and cardiovascular/thrombosis prevention role using the MeSH term anchor, covering a distinct clinical dimension. active
Ropeginterferon alfa-2b (Besremi) pubmed "pegylated interferon"[Title/Abstract] AND ("polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract] OR "myeloproliferative"[Title/Abstract]) AND ("allele burden"[Title/Abstract] OR "disease modification"[Title/Abstract] OR "molecular remission"[Title/Abstract] OR "hematologic response"[Title/Abstract]) The existing 'ropeginterferon' query covers that specific drug name, but this query captures broader pegylated interferon literature (including ropeg studies that may not use the brand/INN name) focused on the disease-modifying outcomes central to this page's concept. active
Ruxolitinib pubmed "ruxolitinib"[Title/Abstract] AND ("splenomegaly"[Title/Abstract] OR "allele burden"[Title/Abstract] OR "JAK inhibitor"[Title/Abstract] OR "resistance"[Title/Abstract] OR "suboptimal response"[Title/Abstract]) AND (myelofibrosis[Title/Abstract] OR "polycythemia vera"[Title/Abstract]) The existing ruxolitinib query is broad; this targets mechanistic and clinical outcome dimensions (splenomegaly reduction, allele burden, resistance/suboptimal response) not covered by any current query, aligning with the page's current understanding. active
Clonal hematopoiesis pubmed ("hematopoietic stem cell"[Title/Abstract] OR "stem cell competition"[Title/Abstract] OR "clonal architecture"[Title/Abstract] OR "allele burden"[Title/Abstract]) AND ("JAK2"[Title/Abstract] OR "CALR"[Title/Abstract] OR "myeloproliferative"[Title/Abstract]) AND ("clonal expansion"[Title/Abstract] OR "clonal evolution"[Title/Abstract] OR "variant allele frequency"[Title/Abstract]) Targets the stem-cell competition and clonal architecture angle of clonal hematopoiesis in MPNs, which the existing 'clonal hematopoiesis' dynamic query doesn't capture at the mechanistic stem-cell level. active
CALR mutations pubmed ("mutant CALR"[Title/Abstract] OR "CALR mutation"[Title/Abstract] OR "calreticulin mutation"[Title/Abstract]) AND ("immunotherapy"[Title/Abstract] OR "antibody"[Title/Abstract] OR "vaccine"[Title/Abstract] OR "targeted therapy"[Title/Abstract] OR "neoantigen"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract] OR "myelofibrosis"[Title/Abstract]) Existing CALR query covers exon 9/type/MPL mechanistic angle; this query targets the immunotherapy and directed-agent therapeutic angle highlighted in recent findings, which no existing query captures. demoted
JAK-STAT signaling pubmed "JAK2"[Title/Abstract] AND ("STAT3"[Title/Abstract] OR "STAT5"[Title/Abstract]) AND ("signaling pathway"[Title/Abstract] OR "signal transduction"[Title/Abstract] OR "phosphorylation"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "myelofibrosis"[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract]) Existing queries cover JAK-STAT broadly and JAK2 V617F structurally (JH2/pseudokinase), but none specifically target the downstream STAT3/STAT5 effector signaling mechanics that are central to this page's focus on constitutive pathway activation in MPN clonal proliferation. demoted
Pelabresib (BET bromodomain inhibitor) biorxiv pelabresib CPI-0610 BET bromodomain myelofibrosis Targets pelabresib (CPI-0610) specifically by both brand name and compound ID alongside BET bromodomain and myelofibrosis, distinct from the existing INCB057643 BET query which covers a different BET inhibitor compound. manually-archived
Pelabresib (BET bromodomain inhibitor) pubmed "pelabresib"[Title/Abstract] OR "CPI-0610"[Title/Abstract] Targets pelabresib by both its generic name and trial compound identifier, which existing queries (including the BET bromodomain inhibitor query) do not explicitly cover, ensuring retrieval of all clinical and preclinical papers on this specific agent. active
Phlebotomy-only maintenance in PV biorxiv phlebotomy polycythemia vera hematocrit cytoreduction low-risk treatment outcome Targets phlebotomy-only management strategy in PV specifically, which is not covered by existing queries that focus on drug therapies, JAK2 signaling, or thrombosis risk factors. manually-archived
Phlebotomy-only maintenance in PV pubmed "phlebotomy"[Title/Abstract] AND ("polycythemia vera"[Title/Abstract] OR "polycythaemia vera"[Title/Abstract]) AND ("low-risk"[Title/Abstract] OR "hematocrit"[Title/Abstract] OR "cytoreduction"[Title/Abstract] OR "aspirin"[Title/Abstract] OR "monotherapy"[Title/Abstract]) Targets phlebotomy as a standalone or primary treatment strategy in PV specifically, which no existing query covers — existing hydroxyurea query touches cytoreduction but not phlebotomy-only management. active
Mutant-selective JAK2V617F inhibition via JH2 pseudokinase domain biorxiv JAK2V617F pseudokinase JH2 allosteric inhibitor mutant-selective Targets the specific mechanistic concept of JH2 pseudokinase domain-directed mutant-selective JAK2V617F inhibition, which no existing query covers; distinct from the broader JAK2 STAT signaling query and from active-site/Type II inhibitor queries. manually-archived
Mutant-selective JAK2V617F inhibition via JH2 pseudokinase domain pubmed "JH2"[Title/Abstract] AND ("pseudokinase"[Title/Abstract] OR "allosteric"[Title/Abstract]) AND ("JAK2"[Title/Abstract] OR "JAK2V617F"[Title/Abstract] OR "V617F"[Title/Abstract]) Targets the JH2 pseudokinase domain allosteric mechanism specifically, which no existing query covers — existing queries address JAK-STAT signaling broadly or ruxolitinib/pan-JAK inhibitors but not the mutant-selective JH2-directed inhibition concept. demoted
Bone marrow fibrosis biorxiv bone marrow fibrosis reticulin collagen myelofibrosis stroma progression Targets the stromal/fibrotic mechanism specific to bone marrow fibrosis in MPN, which none of the existing queries address directly. manually-archived
Bone marrow fibrosis pubmed "bone marrow fibrosis"[Title/Abstract] AND ("reticulin"[Title/Abstract] OR "collagen fibrosis"[Title/Abstract] OR "fibrosis grade"[Title/Abstract] OR "TGF-beta"[Title/Abstract] OR "transforming growth factor"[Title/Abstract]) AND (myelofibrosis[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract] OR myeloproliferative[Title/Abstract]) Targets the mechanistic drivers and grading of marrow fibrosis (reticulin, collagen, TGF-beta) specifically in MPNs, which no existing query addresses. active
ASTX727 (oral cedazuridine + decitabine) biorxiv cedazuridine decitabine oral hypomethylating myeloproliferative neoplasm Targets the oral cedazuridine+decitabine combination (ASTX727) specifically in MPN context, distinct from the existing 'decitabine cedazuridine venetoclax CMML' query by omitting venetoclax/BCL-2 and broadening to MPN applications including iadademstat combinations. manually-archived
ASTX727 (oral cedazuridine + decitabine) pubmed ("ASTX727"[Title/Abstract] OR "cedazuridine"[Title/Abstract] OR "oral decitabine"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "myelofibrosis"[Title/Abstract] OR "MPN"[Title/Abstract] OR "MDS/MPN"[Title/Abstract]) AND ("iadademstat"[Title/Abstract] OR "LSD1"[Title/Abstract] OR "decitabine"[Title/Abstract]) Targets ASTX727/cedazuridine in MPN contexts beyond the existing venetoclax+CMML query, capturing the iadademstat combination trial and broader MPN/MDS-MPN decitabine oral formulation studies not covered by existing queries. demoted
Selinexor + Ruxolitinib combination biorxiv selinexor ruxolitinib combination myelofibrosis XPO1 JAK inhibitor Targets the specific combination therapy of selinexor plus ruxolitinib in myelofibrosis, which is not covered by existing queries that treat selinexor (XPO1) and ruxolitinib as separate topics. manually-archived
Selinexor + Ruxolitinib combination pubmed "selinexor"[Title/Abstract] AND "ruxolitinib"[Title/Abstract] AND ("myelofibrosis"[Title/Abstract] OR "myeloproliferative"[Title/Abstract]) The existing XPO1/selinexor query covers selinexor broadly in MPNs, but this query specifically targets the selinexor+ruxolitinib combination, which is the precise focus of this concept page and not captured by any existing query. active
XPO1 nuclear export biorxiv XPO1 exportin-1 nuclear export selinexor myeloproliferative neoplasm myelofibrosis No existing query targets XPO1/exportin-1 inhibition or selinexor in the MPN context; this directly captures mechanistic and clinical preprints on nuclear export blockade in myeloproliferative neoplasms. manually-archived
XPO1 nuclear export pubmed "XPO1"[Title/Abstract] AND ("selinexor"[Title/Abstract] OR "nuclear export"[Title/Abstract] OR "exportin"[Title/Abstract]) AND ("myelofibrosis"[Title/Abstract] OR "myeloproliferative"[Title/Abstract] OR "polycythemia vera"[Title/Abstract]) Targets XPO1/exportin-1 nuclear export inhibition in MPN contexts directly, which no existing query covers—selinexor appears only in the static page findings and is not captured by any current dynamic query. demoted
Thrombosis risk biorxiv thrombosis polycythemia vera essential thrombocythemia hematocrit platelet JAK2 V617F risk Targets thrombotic risk mechanisms specific to PV/ET (hematocrit, platelet activation, JAK2 V617F allele burden) on biorxiv, which no existing query covers. manually-archived
Thrombosis risk pubmed ("thrombosis"[Title/Abstract] OR "thromboembolic"[Title/Abstract]) AND ("hematocrit"[Title/Abstract] OR "leukocytosis"[Title/Abstract] OR "platelet activation"[Title/Abstract] OR "allele burden"[Title/Abstract]) AND ("polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract] OR "myeloproliferative"[Title/Abstract]) Targets the mechanistic drivers of thrombosis risk (hematocrit, leukocytosis, platelet activation, allele burden) in MPN specifically, which no existing query captures together. active
Hydroxyurea biorxiv hydroxyurea hydroxycarbamide cytoreduction polycythemia vera essential thrombocythemia resistance intolerance Targets hydroxyurea-specific cytoreduction, resistance, and intolerance in PV/ET — not covered by any existing query which focus on JAK inhibitors, interferons, epigenetics, or other agents. manually-archived
Hydroxyurea pubmed "hydroxyurea"[Title/Abstract] AND ("polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract] OR "myeloproliferative"[Title/Abstract]) AND (resistance[Title/Abstract] OR intolerance[Title/Abstract] OR cytoreduction[Title/Abstract] OR "hematocrit"[Title/Abstract]) Targets hydroxyurea specifically in MPN contexts with clinically relevant modifiers (resistance, intolerance, cytoreduction, hematocrit) that none of the existing queries cover. active
ASTX727 + Venetoclax combination (CMML / MDS-MPN) biorxiv decitabine cedazuridine venetoclax CMML myelodysplastic myeloproliferative BCL-2 Targets the specific oral HMA (ASTX727/decitabine-cedazuridine) plus venetoclax combination in CMML/MDS-MPN, which is not covered by existing queries that focus on azacitidine, JAK inhibitors, or other mechanisms. manually-archived
ASTX727 + Venetoclax combination (CMML / MDS-MPN) pubmed ("ASTX727"[Title/Abstract] OR "decitabine cedazuridine"[Title/Abstract] OR "oral decitabine"[Title/Abstract]) AND "venetoclax"[Title/Abstract] AND ("CMML"[Title/Abstract] OR "chronic myelomonocytic leukemia"[Title/Abstract] OR "MDS/MPN"[Title/Abstract] OR "myelodysplastic myeloproliferative"[Title/Abstract]) Targets the specific oral HMA + BCL-2 inhibitor combination in the CMML/MDS-MPN population, which no existing query covers — existing queries touch hypomethylating agents broadly but not ASTX727 specifically nor its pairing with venetoclax. demoted
Inflammatory cytokine signaling biorxiv interleukin cytokine TNF myeloproliferative neoplasm inflammation constitutional symptoms Targets the specific inflammatory cytokine signaling mechanism (IL-6, IL-8, TNF-alpha, constitutional symptoms) in MPNs, which is not covered by any existing query focused on JAK/STAT, clonal hematopoiesis, specific drugs, or mutations. manually-archived
Inflammatory cytokine signaling pubmed ("IL-6"[Title/Abstract] OR "interleukin-6"[Title/Abstract] OR "TNF-alpha"[Title/Abstract] OR "tumor necrosis factor"[Title/Abstract] OR "IL-8"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "myelofibrosis"[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract]) Targets the specific cytokines (IL-6, IL-8, TNF-alpha) named in the page's current understanding in the MPN context, which no existing query covers. active
MPL mutations biorxiv MPL W515 mutation thrombopoietin receptor JAK2 activation essential thrombocythemia myelofibrosis Targets MPL-specific activating mutations (W515L/K) and their mechanistic role in ET/PMF, which the existing CALR query only peripherally touches and no other query addresses directly. manually-archived
MPL mutations pubmed "MPL"[Title/Abstract] AND ("W515L"[Title/Abstract] OR "W515K"[Title/Abstract] OR "MPL mutation"[Title/Abstract] OR "thrombopoietin receptor"[Title/Abstract]) AND ("essential thrombocythemia" OR "myelofibrosis" OR "myeloproliferative") Targets MPL-specific activating mutations (W515L/K) and the thrombopoietin receptor directly, which no existing query covers; the closest existing query only mentions MPL as a secondary term alongside CALR. active
INCB057643 (BET bromodomain inhibitor) biorxiv INCB057643 BET bromodomain inhibitor myelofibrosis Targets INCB057643 specifically as a BET bromodomain inhibitor in myeloproliferative/myelofibrosis context, which no existing query covers. manually-archived
INCB057643 (BET bromodomain inhibitor) pubmed "INCB057643"[Title/Abstract] OR ("BET bromodomain inhibitor"[Title/Abstract] AND ("myelofibrosis"[Title/Abstract] OR "myeloproliferative"[Title/Abstract])) Targets INCB057643 specifically and BET bromodomain inhibitors in MPN context, which no existing static or dynamic query covers. active
INCA033989 (novel investigational agent for MPN) biorxiv INCA033989 calreticulin antibody myeloproliferative neoplasm Targets the specific investigational anti-CALR agent INCA033989 by name alongside its mechanism context, which no existing query covers. manually-archived
INCA033989 (novel investigational agent for MPN) pubmed "INCA033989"[Title/Abstract] Directly targets this specific investigational anti-CALR antibody by its compound name, which no existing query covers. demoted
DNA hypomethylation and epigenetic reprogramming biorxiv DNA hypomethylation epigenetic reprogramming myeloproliferative neoplasm decitabine azacitidine Targets the mechanistic basis of hypomethylating agent activity in MPNs—specifically DNA hypomethylation and epigenetic reprogramming—which none of the existing queries address. manually-archived
DNA hypomethylation and epigenetic reprogramming pubmed ("DNA hypomethylation"[Title/Abstract] OR "hypomethylating agent"[Title/Abstract] OR "epigenetic reprogramming"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "myelofibrosis"[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract]) Targets DNA hypomethylation and epigenetic reprogramming mechanisms specifically in MPN contexts, which no existing static or dynamic query covers. demoted
CALR mutations biorxiv CALR mutation calreticulin exon9 frameshift MPL thrombopoietin receptor myeloproliferative Targets the specific CALR exon 9 frameshift mechanism and MPL receptor activation in ET/PMF, which none of the existing queries cover. manually-archived
CALR mutations pubmed "CALR"[Title/Abstract] AND ("exon 9"[Title/Abstract] OR "type 1"[Title/Abstract] OR "type 2"[Title/Abstract] OR "MPL"[Title/Abstract]) AND ("essential thrombocythemia" OR "myelofibrosis" OR "myeloproliferative") The existing static query covers 'calreticulin' broadly, but this query specifically targets CALR mutation mechanistic details (exon 9 frameshift, type 1/2, MPL activation) in MPN context, which the current queries miss. active
Diet and Nutrition biorxiv diet nutrition inflammation myeloproliferative neoplasm Targets dietary and nutritional interventions in MPN patients, covering anti-inflammatory diet, iron management, and supplement studies not captured by any existing signaling- or treatment-focused queries. manually-archived
Diet and Nutrition pubmed ("diet"[Title/Abstract] OR "nutrition"[Title/Abstract] OR "Mediterranean diet"[Title/Abstract] OR "anti-inflammatory diet"[Title/Abstract] OR "iron intake"[Title/Abstract]) AND ("myeloproliferative" OR "polycythemia vera" OR "myelofibrosis" OR "essential thrombocythemia") Targets dietary and nutritional interventions specifically in MPN populations, which none of the existing static or dynamic queries address. demoted
Ropeginterferon alfa-2b (Besremi) biorxiv ropeginterferon alfa-2b polycythemia vera JAK2 allele burden Targets ropeginterferon/Besremi specifically in PV with allele burden reduction, which none of the existing queries cover. manually-archived
Ropeginterferon alfa-2b (Besremi) pubmed "ropeginterferon"[Title/Abstract] AND ("polycythemia vera" OR "myeloproliferative" OR "JAK2") Targets ropeginterferon (Besremi) specifically by name, which no existing static or dynamic query covers, capturing clinical trials, efficacy, and allele burden reduction studies for this drug. active
Ruxolitinib biorxiv ruxolitinib myelofibrosis JAK inhibitor splenomegaly response Targets ruxolitinib-specific clinical and mechanistic preprints on biorxiv, covering splenomegaly reduction and JAK inhibition in myelofibrosis, which is not addressed by the existing JAK2/STAT signaling or clonal hematopoiesis queries. manually-archived
Ruxolitinib pubmed "ruxolitinib"[Title/Abstract] AND (myelofibrosis OR "polycythemia vera" OR "myeloproliferative") Directly targets ruxolitinib-specific literature in MPN contexts, which no existing static or dynamic query captures despite it being the page's core concept. active
Clonal hematopoiesis biorxiv clonal hematopoiesis stem cell expansion myeloproliferative allele burden Targets clonal hematopoiesis dynamics (allele burden, stem-cell competition, clonal architecture) in the MPN context, which is distinct from the existing JAK2/STAT signaling query and not yet covered by any biorxiv static queries. manually-archived
Clonal hematopoiesis pubmed "clonal hematopoiesis"[Title/Abstract] AND ("myeloproliferative" OR "polycythemia vera" OR "myelofibrosis" OR "essential thrombocythemia") Directly targets clonal hematopoiesis in the MPN context, which the existing dynamic query only partially covers via CHIP/JAK2 pairing, capturing allele burden, stem-cell competition, and clonal architecture studies not retrieved by current queries. demoted
JAK-STAT signaling biorxiv JAK2 STAT signaling myeloproliferative Targets biorxiv preprints on JAK2-STAT pathway mechanisms in MPNs, covering mechanistic studies not yet in peer-reviewed journals and not duplicated by any existing queries. manually-archived
JAK-STAT signaling pubmed "JAK-STAT"[Title/Abstract] AND ("myeloproliferative" OR "myelofibrosis" OR "polycythemia vera" OR "essential thrombocythemia") Targets the JAK-STAT signaling pathway phrase directly, which is not covered by existing queries that focus on JAK2 V617F mutation or disease MeSH terms alone. demoted

Demoted this run

PageSourceQueryReason
ASTX727 (oral cedazuridine + decitabine) pubmed ("ASTX727"[Title/Abstract] OR "cedazuridine"[Title/Abstract] OR "oral decitabine"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "MPN"[Title/Abstract] OR "myelofibrosis"[Title/Abstract] OR "CMML"[Title/Abstract] OR "MDS/MPN"[Title/Abstract]) AND ("pharmacokinetics"[Title/Abstract] OR "bioavailability"[Title/Abstract] OR "clinical trial"[Title/Abstract] OR "phase"[Title/Abstract] OR "response"[Title/Abstract]) 0 relevant hits over 9 scans (min 1)
ASTX727 + Venetoclax combination (CMML / MDS-MPN) pubmed "venetoclax"[Title/Abstract] AND ("CMML"[Title/Abstract] OR "chronic myelomonocytic leukemia"[Title/Abstract] OR "MDS/MPN"[Title/Abstract]) AND ("BCL-2"[Title/Abstract] OR "BCL2"[Title/Abstract]) AND ("hypomethylating"[Title/Abstract] OR "azacitidine"[Title/Abstract] OR "decitabine"[Title/Abstract]) 0 relevant hits over 9 scans (min 1)
Inflammatory cytokine signaling pubmed ("inflammatory cytokine"[Title/Abstract] OR "cytokine storm"[Title/Abstract] OR "cytokine profile"[Title/Abstract] OR "proinflammatory"[Title/Abstract]) AND ("constitutional symptoms"[Title/Abstract] OR "fatigue"[Title/Abstract] OR "pruritus"[Title/Abstract] OR "clonal advantage"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "myelofibrosis"[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract]) 0 relevant hits over 9 scans (min 1)
MPL mutations pubmed "MPL"[Title/Abstract] AND ("W515"[Title/Abstract] OR "S505"[Title/Abstract] OR "Y591"[Title/Abstract] OR "R592"[Title/Abstract] OR "exon 10"[Title/Abstract]) AND ("thrombopoietin receptor"[Title/Abstract] OR "JAK2 activation"[Title/Abstract] OR "signaling"[Title/Abstract]) AND ("essential thrombocythemia" OR "myelofibrosis" OR "myeloproliferative") 0 relevant hits over 9 scans (min 1)
Diet and Nutrition pubmed ("Mediterranean diet"[Title/Abstract] OR "anti-inflammatory diet"[Title/Abstract] OR "dietary iron"[Title/Abstract] OR "iron intake"[Title/Abstract] OR "nutrition"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "myelofibrosis"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract]) 0 relevant hits over 10 scans (min 1)
Pelabresib (BET bromodomain inhibitor) pubmed "pelabresib"[Title/Abstract] AND ("ruxolitinib"[Title/Abstract] OR "JAK inhibitor"[Title/Abstract] OR "combination therapy"[Title/Abstract] OR "spleen volume"[Title/Abstract] OR "symptom burden"[Title/Abstract]) AND ("myelofibrosis"[Title/Abstract] OR "myeloproliferative"[Title/Abstract]) 0 relevant hits over 10 scans (min 1)
Phlebotomy-only maintenance in PV pubmed "phlebotomy"[Title/Abstract] AND ("polycythemia vera"[Title/Abstract] OR "polycythaemia vera"[Title/Abstract]) AND ("low-risk"[Title/Abstract] OR "maintenance"[Title/Abstract] OR "watchful waiting"[Title/Abstract] OR "aspirin alone"[Title/Abstract] OR "without cytoreduction"[Title/Abstract]) 0 relevant hits over 10 scans (min 1)
INCA033989 (novel investigational agent for MPN) pubmed "INCA033989"[Title/Abstract] OR ("anti-CALR"[Title/Abstract] AND "monoclonal antibody"[Title/Abstract] AND ("myeloproliferative"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract] OR "myelofibrosis"[Title/Abstract])) 0 relevant hits over 10 scans (min 1)
CALR mutations pubmed ("mutant CALR"[Title/Abstract] OR "CALR mutation"[Title/Abstract] OR "calreticulin mutation"[Title/Abstract]) AND ("immunotherapy"[Title/Abstract] OR "antibody"[Title/Abstract] OR "vaccine"[Title/Abstract] OR "targeted therapy"[Title/Abstract] OR "neoantigen"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract] OR "myelofibrosis"[Title/Abstract]) 0 relevant hits over 11 scans (min 1)
JAK-STAT signaling pubmed "JAK2"[Title/Abstract] AND ("STAT3"[Title/Abstract] OR "STAT5"[Title/Abstract]) AND ("signaling pathway"[Title/Abstract] OR "signal transduction"[Title/Abstract] OR "phosphorylation"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "myelofibrosis"[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract]) 0 relevant hits over 11 scans (min 1)
Mutant-selective JAK2V617F inhibition via JH2 pseudokinase domain pubmed "JH2"[Title/Abstract] AND ("pseudokinase"[Title/Abstract] OR "allosteric"[Title/Abstract]) AND ("JAK2"[Title/Abstract] OR "JAK2V617F"[Title/Abstract] OR "V617F"[Title/Abstract]) 0 relevant hits over 12 scans (min 1)
ASTX727 (oral cedazuridine + decitabine) pubmed ("ASTX727"[Title/Abstract] OR "cedazuridine"[Title/Abstract] OR "oral decitabine"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "myelofibrosis"[Title/Abstract] OR "MPN"[Title/Abstract] OR "MDS/MPN"[Title/Abstract]) AND ("iadademstat"[Title/Abstract] OR "LSD1"[Title/Abstract] OR "decitabine"[Title/Abstract]) 0 relevant hits over 13 scans (min 1)
XPO1 nuclear export pubmed "XPO1"[Title/Abstract] AND ("selinexor"[Title/Abstract] OR "nuclear export"[Title/Abstract] OR "exportin"[Title/Abstract]) AND ("myelofibrosis"[Title/Abstract] OR "myeloproliferative"[Title/Abstract] OR "polycythemia vera"[Title/Abstract]) 0 relevant hits over 13 scans (min 1)
ASTX727 + Venetoclax combination (CMML / MDS-MPN) pubmed ("ASTX727"[Title/Abstract] OR "decitabine cedazuridine"[Title/Abstract] OR "oral decitabine"[Title/Abstract]) AND "venetoclax"[Title/Abstract] AND ("CMML"[Title/Abstract] OR "chronic myelomonocytic leukemia"[Title/Abstract] OR "MDS/MPN"[Title/Abstract] OR "myelodysplastic myeloproliferative"[Title/Abstract]) 0 relevant hits over 4 scans (min 1)
INCA033989 (novel investigational agent for MPN) pubmed "INCA033989"[Title/Abstract] 0 relevant hits over 4 scans (min 1)
DNA hypomethylation and epigenetic reprogramming pubmed ("DNA hypomethylation"[Title/Abstract] OR "hypomethylating agent"[Title/Abstract] OR "epigenetic reprogramming"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "myelofibrosis"[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract]) 0 relevant hits over 4 scans (min 1)
Diet and Nutrition pubmed ("diet"[Title/Abstract] OR "nutrition"[Title/Abstract] OR "Mediterranean diet"[Title/Abstract] OR "anti-inflammatory diet"[Title/Abstract] OR "iron intake"[Title/Abstract]) AND ("myeloproliferative" OR "polycythemia vera" OR "myelofibrosis" OR "essential thrombocythemia") 0 relevant hits over 4 scans (min 1)
Clonal hematopoiesis pubmed "clonal hematopoiesis"[Title/Abstract] AND ("myeloproliferative" OR "polycythemia vera" OR "myelofibrosis" OR "essential thrombocythemia") 0 relevant hits over 4 scans (min 1)
JAK-STAT signaling pubmed "JAK-STAT"[Title/Abstract] AND ("myeloproliferative" OR "myelofibrosis" OR "polycythemia vera" OR "essential thrombocythemia") 0 relevant hits over 4 scans (min 1)

Subscribe: calendar of upcoming dates · deadlines feed · all new records · Help

build build 612 · 69ce4cf-dirty · 2026-11-11